Good news from France

We are glad to inform community that clinical trial for AZP2006 (ALZPROTECT biotech) involving 36 patients for a called "phase 2a", has eventually started and and will recruit until spring 2021. AZP2006 is claimed to target different disorder than monoclonal antibodies. Only 2 hospitals are recruiting in France for that trial.

34 views0 comments

Recent Posts

See All
Promotus Logo.png
Promotus Logo.png